Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Phase I Study of the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Dose of ETI-204 (Anthim) [Elusys Protocol Number AH-102].

Trial Profile

Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Phase I Study of the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Dose of ETI-204 (Anthim) [Elusys Protocol Number AH-102].

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Obiltoxaximab (Primary)
  • Indications Anthrax
  • Focus Adverse reactions
  • Sponsors EluSys Therapeutics
  • Most Recent Events

    • 14 Sep 2016 According to an Elusys Therapeutics media release, results from this study are published online at Clinical Therapeutics.
    • 24 Aug 2016 Results assessing safety, immunogenicity, and pharmacokinetics of this and other four studies published in the Clinical Therapeutics
    • 21 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top